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ABSTRACT
Hypertrophic (HTSs) and keloid scars are
common dermatological complaints produced
by disruption of the normal wound-healing
process. Despite a wide array of therapeutic
options available to treat these lesions, HTSs
and keloids continue to pose a significant
challenge to clinicians in everyday practice.
The chemotherapeutic drug 5-fluorouracil
(5-FU) is a well-known treatment option
reserved for recalcitrant HTSs and keloid
lesions. We present clinicians with a
comprehensive review of the published data
concerning the use of 5-FU in the treatment of
HTSs and keloids. The current evidence suggests
that 5-FU is a safe and practical alternative for
the treatment of HTSs and keloids as it may
substantially improve the appearance of
proliferative scars and reduce the chance of
recurrence. This therapeutic option is most
effective in conjunction with adjuvant therapy
such as corticosteroids. Additional randomized
controlled clinical trials with large sample sizes
should be conducted to corroborate the existing
efficacy and safety data in patients with HTSs
and keloids.
Keywords: 5-FU; Fluorouracil; Hypertrophic
scars; Keloids; Scars
INTRODUCTION
Hypertrophic (HTSs) and keloid scars are
commonly encountered complaints in
dermatological practice [1]. These abnormal
lesions are clinically challenging to treat and
can be a source of significant distress to both
patients and providers [2]. Lesions exhibit no
gender preference, but principally emerge in
younger individuals and ethnicities with darker
complexions, such as African Americans,
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Asians, and Hispanics [1, 3]. An estimated
5–16% of African Americans and Hispanics
experience keloid lesions [1]. Additional risk
factors include a personal history of
proliferative scars, a family history of HTSs or
keloids, and inflammation in and around a
wound site [4]. There is currently no
explanation for the underlying pathogenesis of
HTSs and keloids. These lesions may depict an
aberrant wound-healing response to external
physical trauma and represent an underlying
complication of the extracellular matrix
remodeling process [3, 5]. Lesions can present
anywhere on the skin surface where physical
trauma has occurred; however the ear lobes,
face, arms, shoulders, back, and chest are the
most commonly afflicted anatomic locations.
HTSs and keloids are differentiated clinically by
the extent of tissue overgrowth with respect to
the boundaries of the original wound [6]. HTSs
are white to pink colored and persist along the
margins of the original wound [7].
Contrastingly, keloid lesions are deep red to
purple and have the capacity to proliferate well
beyond the original borders of the wound [3, 5,
8]. Table 1 compares non-hypertrophic and
fibroproliferative scars.
Reasons to pursue treatment for HTSs and
keloids include aesthetic considerations related
to the psychological stress of cosmetic
disfigurement or physical complaints
including pain and pruritus [9]. Countless
pharmacological agents have been investigated
as monotherapy or in various combinations for
scar therapy such as surgical excision, occlusive
dressings, topical and intralesional
corticosteroids, interferon, cryosurgery,
radiation, pressure therapy, laser therapy,
retinoic acid, and silicone gel sheeting [7].
Recently published studies investigate the
value of laser therapy, including the
flash-lamp pulsed dye, fractional carbon
dioxide laser, copper bromide laser, and UVA1
laser [10–13]. Despite an array of therapeutic
approaches, no single method provides
complete benefit. For this reason, the medical
care of HTSs and keloids remains clinically
challenging, owing to variable efficacies, side
effect profiles, and high instances of recurrence
[3].
Chemotherapeutic drugs are also utilized as a
treatment option for recalcitrant and recurrent
HTSs and keloids [14]. Five-fluorouracil (5-FU) is
a pyrimidine analog that inhibits the synthesis
of deoxyribonucleic acids by irreversibly
inhibiting thymidine synthase, which is
responsible for converting uridine to
thymidine. Without the structural elements of
biosynthesis, rapidly proliferating cells such as
fibroblasts are halted and scar degradation is
Table 1 Comparison of non-hypertrophic scars and ﬁbroproliferative scars [39]
Scar type Scar type subclass Clinical characteristics
Non-hypertrophic Atrophic Depressed
Textural Mature light color, ﬂat
Immature red, pruritic, painful, slightly elevated
Fibroproliferative Hypertrophic Linear red, raised, pruritic
Widespread red, raised, pruritic, extensive
Keloids Minor focally raised, pruritic
Major[0.5 cm, painful, pruritic
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promoted [4]. Additionally, 5-FU is believed to
hinder type I collagen gene expression and the
effects of tumor growth-beta 1. Studies have
discovered a dose-related association between
5-FU and reduction in keloid fibroblast
proliferation and the fibroblast-populated
collagen lattice. In 1999, Fitzpatrick first
introduced 5-FU for the treatment of HTSs and
keloids [15]. Subsequent investigators have
endorsed 5-FU as a viable treatment option
and have explored 5-FU combined with
adjuvant modalities to enhance its efficacy
[16]. In this comprehensive review, we provide
clinicians with the currently published studies
involving 5-FU for the treatment of HTSs and
keloids.
METHODS
We sought to obtain all available published data
that studied the treatment of HTSs and keloids
with 5-FU as an individual agent or 5-FU plus
adjuvant treatment. For the purposes of this
review, the agents considered adjuvant
treatments included corticosteroids, lasers,
botulinum toxin, or silicone sheets.
Importantly, excision was not considered
adjuvant treatment, and the combination of
excision and 5-FU was considered
monotherapy. A broad literature search in
PubMed, Medline, EMBASE, Cochrane Central
Register of Controlled Trials (CENTRAL), and
Google Scholar was performed on November
2015. To search for the conditions of interest,
we used the terms 5-FU, fluorouracil,
hypertrophic scar, keloid, and scar in various
combinations. The search strategy for PubMed
is shown in Appendix 1 (Electronic
Supplementary Material). Only citations in
English and involving human subjects were
included. Studies published online and in print
and from all years were considered. Titles and
abstracts were screened for relevance to our
topic. Two authors independently reviewed the
relevant full text articles and each extracted
datum, which was consolidated into a
standardized table. A third author resolved any
differences. Reference lists of the included trials
were screened for additional eligible
publications. The search was rerun in
December, January, and February for recently
published articles. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
The preliminary literature search produced 147
citations. After filtering the search according to
inclusion criteria, 69 titles and abstracts were
screened for relevance. After screening, a total
of 21 articles were included in this review. The
selected articles include: ten randomized
controlled trials, four prospective single-arm
trials, four case series, two case report(s), and
an expert opinion. Table 2 presents the
treatment regimen and clinical outcomes of
studies involving intralesional 5-FU
monotherapy and intralesional 5-FU with
adjuvant corticosteroid therapy.
Intralesional 5-FU Monotherapy
Gupta and Kalra treated 24 consecutive patients
with 50–150 mg intralesional injections of
50 mg/ml of 5-FU using 1-week injection
intervals for a total of 16 injections. Clinical
evaluation by a single observer was done at
treatment, cessation of treatment, and the
follow-up period. Excellent flattening was seen
in 33.3% of patients, and more than 70%
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patients reported decreased itching, pain, and
discharge. Side effects of treatment included
pain and hyperpigmentation in all 24 patients
as well as ulceration in 1 patient. There were no
reoccurrences in patients who were followed up
at 3–6 months [17].
In a similar study, Nanda and Reddy studied
the effects of 5-FU in 28 patients with keloids on
the chest, shoulder, upper arms, back, and
additional locations. Eight patients had
previously failed to respond to triamcinolone
acetonide (TAC) 40 mg/cc injections every
3 weeks. Weekly intralesional injections of
0.5–2 ml of 50 mg/ml 5-FU per session were
administered for no more than 12 weeks. There
was good improvement in 71.4% patients and
excellent improvement in 7.1% patients.
Follow-up at 24 weeks revealed no recurrences.
Adverse effects included pain in 100%,
ulceration in 21.4%, and burning in 7.1% of
patients [18].
Kontochristopoulus et al. also investigated
the effects of intralesional 5-FU in 20 patients
with keloid lesions on various locations
including the chest, back, extremities, and
earlobes. Eleven patients had previously failed
treatment with steroid injections, silicone gels,
surgical excision, and cryotherapy. Weekly
intralesional injections of 0.2–0.4 ml/cm2 of
50 mg/ml 5-FU were administered over an
average of seven sessions. Forty percent of
patients had good improvement, and 5% had
excellent improvement. At 52-week follow-up,
47% demonstrated reoccurrence. All patients
experienced pain and transient
hyperpigmentation, and six patients had
superficial ulceration [19].
Goldan et al. utilized 5-FU injections to treat
a 67-year-old female with facial HTSs and
keloids following dermabrasian facial
resurfacing. The patient had achieved only
mild improvement with previous treatments
including acyclovir, prednisone, fucidic acid,
fexofenadine, betamethasone, and local
silicone sheets with intralesional
methylprednisolone acetate. Serial
intralesional injections of 50 mg/ml 5-FU in
six sessions over 3 months produced significant
improvement of post-dermabrasian HTSs and
keloids, with noticeably smaller, softer scars and
less erythema. Local anesthesia with 1%
lidocaine was administered prior to injections,
and silicone sheets were applied following
treatment. The patient experienced few side
effects throughout the treatment and complete
resolution of pain and pruritus [20].
Haurani et al. evaluated the effects of
excision followed by intralesional 5-FU in 32
patients with keloid lesions and 21 patients
with HTSs. All had previously failed
corticosteroid therapy, and many failed other
conventional treatments. Scars were
administered 50 mg/ml 5-FU intralesional
injections every 2–4 weeks with a total dose of
500 mg. Additionally, keloids were excised
2 weeks prior to the start of intralesional
series. Patients were assessed upon scar
symptom questionnaire and scar volume. Fair
or good improvement was noted in 27% of
patients, and 63% experienced excellent
improvement. Nineteen percent of patients
experienced reoccurrence of lesions at 1-year
follow-up [21].
In a study of 44 patients with keloid lesions,
Saha and Mukhopadhyay compared
intralesional 5-FU to 40 mg/ml TAC injections
(RCT control). Weekly 50-mg/ml intralesional
5-FU was administered over an average of five
sessions. Seventeen of 20 patients (85%) in the
5-FU group achieved fair to excellent flattening
of lesions. Thirty-five percent of patients
experienced reoccurrence of lesions at
6 months post-treatment. Both treatment
regimens were equally effective in reducing
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keloid volume, but the side effects were
noticeably worse in the 5-FU group, with 95%
experiencing extreme pain and 65%
experiencing superficial ulcerations [22].
In a similar manner, Khare and Patil
compared intralesional 5-FU plus excision in
28 patients to intralesional TAC (control) in 24
patients with ear keloids. Patients in the
treatment group received 50–150 mg/ml 5-FU
intralesional injections following excision.
Ninety-six percent of patients in the treatment
group demonstrated reduced keloid size at the
end of 1 year. Fewer instances of recurrences
occurred in the treatment group (4%) as
compared to the control group (22%). Side
effects of therapy included superficial necrosis
in three patients, partial wound dehiscence in
two patients, and local infection in one patient
[23].
Prabhu et al. also compared the efficacy of
weekly intralesional injections of 50 mg/ml
5-FU versus 40 mg/ml TAC (control) in 30
patients with keloids for 4 weeks. Interestingly,
good to excellent flattening of keloid size was
seen in 64% of patients in patients receiving
5-FU versus 87% in patients receiving TAC
monotherapy, and the difference was
statistically significant. More complications
were encountered in the 5-FU group and
included ulceration in one patient, pruritus in
one patient, and pain in one patient, but this
distinction was not statistically significant [24].
Intralesional 5-FU/TAC Combination
In a series of observations involving more than
1000 patients over 9 years, Fitzpatrick recorded
the use of 5-FU with and without different
adjuvant therapies for the treatment of various
scar types including keloids. All patients
received intralesional injections of 50 mg/ml
5-FU without ever exceeding 100 mg per
treatment. Initially, patients received 5-FU
monotherapy once monthly, which was found
to be ineffective. With added time and
experience, Fitzpatrick reported reduced pain
and overall better outcomes with once-weekly
injections (on average) of a mixture of 45 mg/
ml 5-FU in combination with 1 mg/ml of TAC
[15].
Manuskiatti and Fitzpatrick conducted a
study involving ten patients with previously
untreated median sternotomy HTSs and keloids.
In a single study, several management options
were compared by separating lesions into five
segments: laser radiation with 585-nm
pulsed-dye laser (PDL), TAC, intralesional
5-FU, and intralesional TAC in combination
with 5-FU (5-FU/TAC), and untreated control.
In 5-FU sections, intralesional injections of
50 mg/ml 5-FU were administered every
2 weeks for the first eight treatments and every
4 weeks for the last two treatments. All treated
segments demonstrated significant
improvement; however, no method
demonstrated superiority over the others.
Intralesional 5-FU and 5-FU/TAC demonstrated
significant lesion flattening as compared with
baseline by week 8. Scar erythema was reduced
at week 16 and week 24 with 5-FU and 5-FU/
TAC, respectively, compared to baseline. Scar
pliability was increased at week 8 with 5-FU/
TAC and by week 16 with 5-FU monotherapy.
Subjects receiving 5-FU revealed 70% with fair
improvement and 30% with good improvement
on self-assessments at 32 weeks. All patients
who received 5-FU with or without adjuvant
treatment noted pain and burning. One patient
on 5-FU/TAC developed superficial ulceration
[25].
Apikan and Goodman also investigated 5-FU
in combination with betamethasone acetate
(BA) and betamethasone sodium phosphate
(BSP) in two patients with keloid scars. A
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mixture of 1.6 ml of 50 mg/ml 5-FU with 0.4 ml
of 3 mg/ml of BA and 3.9 mg/ml of BSP was
injected every 2 weeks for 1 year. The study
demonstrated a reduction in keloid size and
minimal side effects with no recurrences at
1-year follow-up. Side effects included
hyperpigmentation in both patients [26].
Davidson et al. conducted a retrospective
review of 94 patients with 102 keloids. Keloids
were separated into three treatment groups
including: 5-FU/TAC without excision (52
subjects), 5-FU/TAC with excision (24
subjects), and TAC treatment with excision (26
subjects). A 3:1 concentration of 37.5 mg/ml of
5-FU and 10 mg/ml of TAC was mixed, and
0.1 ml of solution per centimeter of lesion was
injected. Excisional patients were given
injections 2, 4, and 6 weeks after surgery, and
non-excisional patients were administered
injections every 4 weeks. A statistically
significant reduction in keloid size was seen
with 5FU/TAC regimens (92%) as compared to
TAC alone (73%). Patients with keloids treated
with 5-FU experienced pain and pruritus [27].
Khan et al. enrolled 150 patients to receive
either intralesional 0.25 ml of 40 mg/ml TAC
diluted with 0.75 ml normal saline or 0.9 ml of
50 mg/ml of 5-FU mixed with 0.1 ml of 40 mg/
ml TAC. There was significant improvement
with 5-FU/TAC compared to TAC monotherapy,
with 63 5-FU/TAC patients (84%) having good
to excellent results compared to 51 TAC
patients (68%). There were no instances of scar
recurrence at 6-month follow-up. Eighteen
patients (24%) who were administered TAC
alone and six patients (8%) who were given
5-FU/TAC experienced complications [28].
Mutalik and Patwardhan studied 30 patients
with HTSs and keloids and administrated
intralesional injections of 50 mg/ml 5-FU. TAC
40 mg/ml was added in a 1:1 ratio for lesions
with inflammation or firm induration. Patients
were instructed to use sodium fusidate or
mupirocin for 5 days following treatment and
follow-up in 4 weeks; 67% of patients showed
complete flattening of keloids with a mean of
four injections. A quarter of these patients who
improved with therapy developed reoccurrence
of lesions at 1-year follow-up. Side effects
included transient hyperpigmentation with
5-FU. Infection and hypopigmentation were
seen in a few patients who received
concomitant steroids [29].
Intralesional 5-FU/TAC and Lasers
Fitzpatrick also recounted successful treatment
of scars with pronounced erythema using
pretreatment with PDL therapy. In a
45-year-old female with HTSs and keloids
following plastic surgery to the face,
Fitzpatrick administered intralesional
injections of 45 mg/ml 5-FU and 1 mg/ml of
TAC over 20 treatment sessions. Follow-up use
of PDL (6.25 J/cm2) demonstrated complete
resolution of HTSs and keloids [15].
Alsilian et al. used lasers in combination
with intralesional 5-FU/TAC for the treatment
of keloids and HTSs. Sixty-nine patients were
divided into three groups receiving different
therapies: TAC 10 mg/ml injected at weekly
intervals for 8 weeks, TAC ? 5-FU 0.1 ml of
40 mg/ml TAC added to 0.9 ml of 5-FU 50 mg/
ml injected weekly for 8 weeks, and 5-FU/TAC
serial injections for 8 weeks, combined with 585
PDL 5–7 J/cm2 at the 1st, 4th, and 8th weeks.
Statistically significant improvement was found
in patients receiving 5-FU/TAC and 5-FU/
TAC ? PDL in contrast to TAC monotherapy.
Average flattening of the lesion was 50% in the
TAC group, 77% in the 5-FU/TAC group, and
79% in the 5-FU/TAC ? PDL groups. Patients in
all three groups complained of pain associated
with injections. Steroid atrophy and
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telangiectasia was seen with TAC monotherapy
[30].
Darougheh et al. randomized 40 HTSs and
keloid patients to receive either TAC alone or
5-FU/TAC. Weekly intralesional injections of
10 mg TAC or a mixture of 4 mg TAC and 45mg
5-FU were given for a total of eight treatments.
There were statistically significant reductions in
length, width, height, erythema, induration, and
pruritus in both groups, with greater
improvement in the 5-FU/TAC group. Greater
than 50% improvement was reported in 20% of
the TAC group versus 55% in the 5-FU/TAC
group. Trained observers also reported greater
improvement in the 5-FU/TAC group; however,
this difference was not statistically significant.
Adverse events included pain, atrophy, and
telangiectasia in those receiving steroids.
Interestingly, the 5-FU/TAC group demonstrated
no adverse effects besides injection pain [31].
Katz et al. described intralesional 5-FU/TAC in
combination laser therapy in a 75-year-old female
who developed perioral, hypertrophic scarring
following a phenol peel for perioral rhytides. She
had previously received intralesional 5-FU/TAC
therapies with no improvement. Katz et al.
attempted 595-nm PDL (7–9 J/cm2, 7–10-mm
spot size, 3–10-ms pulse width, with 21–55
pulses per treatment) followed by the 1450-nm
diode laser (12–14 J/cm2, 6-mm spot size, 6–16
pulses per treatment). After each laser session, the
patient was administered 10 mg/ml intralesional
TAC and 50 mg/ml 5-FU. She experienced greater
than 95% of aesthetic and functional
improvement and no recurrence following ten
treatment sessions. Side effects included
temporary bruising [32].
Additional Techniques
Hatamipour et al. studied the effects of
intralesional 5-FU with topical silicone in the
prevention of keloids. Fifty patients with
keloids of different sizes and varying durations
were used to compare treatment with and
without 5-FU. Any prior therapy was
discontinued before enrollment. In the
treatment group, keloids were excised, covered
with topical silicone sheets, and administered a
series of 50 mg/ml 5-FU intralesional injections
at postsurgical days 7, 14, 28, and during the
2nd and 3rd months, with doses varying
between 0.6 to 1 ml. The second group and
controls received no 5-FU intralesional
treatment; 75% of patients showed complete
improvement versus 43% in the control group.
Side effects included ulceration, burning, and
pain at the injection site [33].
Uppal et al. studied 11 Afro-Caribbean
patients with keloid scars on the earlobes,
chest, or shoulders. Ten patients had
previously received intralesional steroid
treatment. Patients with bilateral earlobe
keloids were randomized into control or
treatment groups according to coin toss, and
linear scars were split in half. Following
excision, treatment lesions were given 50 mg/
ml 5-FU intralesional injections in
phosphate-buffered saline by a soaked sponge
pledget for 5 min. Control lesions were exposed
to phosphate-buffered saline alone. Greater
clinical improvement by lower keloid scar
scores was appreciated in treated lesions than
controls by blinded observers [34].
Sadeghinia and Sadeghinia developed a novel
approach to administer 5-FU named ‘‘5-FU
tattooing.’’ The procedure of 5-FU tattooing
includes anesthesia of lesions followed by
dripping 1 ml of 50 mg/ml of 5-FU solution
onto each centimeter area of the lesion. Forty
punctures are made in the skin using a 27-gauge
needle, and 1 ml of 5-FU solution was again
dripped on the surface and covered in order to
optimize absorption of 5-FU. The study involved
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40 patients randomized into an intralesional TAC
group or 5-FU tattooing group. Patients who
received any other treatment type in the past
6 months were excluded from the study. Patients
received therapy every 4 weeks for a total of
12 weeks. At the end of the study, both groups
demonstrated a reduction in size, erythema,
induration, and pruritus. More than double the
number of patients receiving 5-FU achieved good
to excellent patient satisfaction scores as
compared to those in the TAC group (85%
versus 40%, respectively). Greater overall
improvement was also appreciated by observer
assessment in the 5-FUgroup.Ninety-five percent
of patients in the 5-FU group achieved good to
excellent results, whereas only 50% in the TAC
group achieved a good to excellent response [35].
Wilson et al. utilized botulinum toxin to
enhance the inhibitory effect on fibroblasts.
Following surgical excision, 80 patients with
keloids were injected with intralesional 50 mg/
ml 5-FU with 50 IU/ml botulinum toxin, using a
total dose of less than 140 U. All patients were
treatment failures with various other methods.
Themean follow-up periodwas 19.6 months over
which only 3.75% experienced recurrence. More
than 80% of patients reported significant
improvement and 12.5% conveyed at least
slight improvement. Complications included
pruritus, pain, and residual post-inflammatory
hyperpigmentation. One patient experienced
partial wound dehiscence during the
postoperative period. Eleven patients (13.75%)
experienced late widening of the scar, which
resulted in corrective surgery at a later date in half
[36].
DISCUSSION
Fibroblasts are imperative constituents of the
normal wound-healing processes, of which
there is three distinct stages including
inflammation, proliferation, and maturation
[4]. First, leukocytes and macrophages clean
the wound of cellular debris and bacteria to
prevent infection. Next, fibroblasts produce
collagen, which gives tissue its tensile strength
and structure. The wound site fills with
granulation tissue, and the margins contract
with the mobility of myofibroblasts allowing for
epithelization. In the final phase of wound
healing, collagen fibers remodel to improve the
overall tensile strength [15]. Disruption of this
normal-healing process results in the formation
of HTSs and keloids [15].
A number of new strategies have been
introduced for the treatment of HTSs and
keloids in the past decade or so, including
chemotherapeutic drugs. Observations from
in vitro studies provide scientific evidence of
5-FU’s ability to effectively suppress fibroblast
proliferation and inflammation, thus reducing
postoperative scar formation [37]. Other studies
have also found that fibroblast suppression is
dependent upon the duration and dosage of the
drug. Several clinical studies have also
investigated the effects of intralesional 5-FU
on HTSs and keloids alone or in combination
with other modalities. Thus, 5-FU offers an
alternative management option for patients
with HTSs or keloids experiencing unwanted
effects or those who have previously failed other
treatment options.
Efficacy
Use of intralesional 5-FU monotherapy achieves
good to excellent scar improvement in 45–78%
of patients. This effectiveness is further
augmented with the addition of TAC, where
96% of patients achieve good to excellent
results [2, 5]. Seeing that, the combination of
5-FU and TAC seem to be more effective than
either 5-FU or TAC administered alone [5].
178 Dermatol Ther (Heidelb) (2016) 6:169–183
Granted, a multitude of factors seem to
contribute to the overall efficacy of 5-FU on
HTSs and keloids including, but not limited to,
drug dosage, intralesional regimen, scar size,
and scar duration. Studies investigating the
effects of 5-FU monotherapy used consistent
drug dosages of 50 mg/ml. When combined
with TAC, the steroid combinations remained
very low (TAC: 5-FU of 1:45 or 4:45 mg/ml) [2].
Davison et al. tested greater dosages (TAC: 5-FU
10:37.5 mg/ml) and appreciated increased
instances of side effects, although this was not
statistically significant. Thus, low doses of
corticosteroids are recommended and its
addition primarily functions to reduce the
incidence of unwanted side effects. Also,
lesions are more challenging to treat with
added time, and this is true for 5-FU as well as
the majority of other existing scar therapies as
well [6]. Such was the experience of Gupta and
Kalra, who found a correlation between
therapeutic response and keloid age, with
keloids of less than or equal to 5-year duration
achieving greater flattening than older keloids
[17].
The effects of 585-nm PDL therapy on scars is
well known in the literature [38]. Lasers target
the scar microvasculature by selective
photothermolysis, although the exact
mechanisms by which it improves proliferative
scars are unknown [7]. Very few studies have
explored the effects of adjuvant laser radiation
in the context of 5-FU and scar treatments, but
those that have have successfully demonstrated
positive results [15, 25, 31, 32]. Fitzpatrick was
the first to report his experience with 5-FU and
PDL therapy and noted the benefits of less scar
erythema [15]; of note, a follow-up study
exhibited no superiority in efficacy with the
addition of laser therapy [25]. In the same
manner, Katz et al. were the first to report
successful results of adjuvant therapy with the
1450-diode laser and also reported successful
results [32]. The therapeutic benefits of laser
therapy with 5-FU on scars likely improve scar
texture and erythema [25], but it is difficult to
comment on the exact efficacy of the
combination of laser therapy with 5-FU
because of the minimal evidence available.
Additional studies are needed to clarify its
efficacy with 5-FU, as there is insufficient
evidence of this method.
Safety and Recurrence
5-FU drug toxicity is usually seen with
intravenous dosing and primarily involves
adverse hematologic effects such as anemia,
thrombocytopenia, and leukopenia [34].
Patients with active or chronic infections,
immune depression, and pregnant or lactating
women should avoid 5-FU [39]. No systemic
side effects following injection were observed in
any of the studies discussed in this review.
Several studies reported no side effects, and
those that did reported adverse effects of
erythema, ulceration, and dyspigmentation
and significant pain at the injection site. These
were generally transient or easily manageable.
More serious side effects included dehiscence,
widened scars, and tissue necrosis.
Corticosteroids are highly advantageous
because of their multi-faceted inhibitory
effects including the suppression of fibroblast
and keratinocyte proliferation, reduction in
inflammation, and vasoconstriction of blood
vessels [15]. The disadvantages of potent
corticosteroid use are its unpleasant side
effects including telangiectasia, atrophy,
rebound effects, ineffectiveness, and the pain
of multiple injections [15]. With respect to
corticosteroids, the literature is consistent and
suggests that the 5-FU/TAC combination
regimen is most effective on keloid scars and
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decreases 5-FU induced erythema and
inflammation. Furthermore, the combination
of 5-FU with corticosteroids decreases the
incidence of such side effects that can be
affiliated with steroid monotherapy.
Treatment intervals between injections may
correlate with instances of side effects.
Fitzpatrick achieved the best results with
once-weekly injection intervals, which is
commonly accepted [15]. Some studies also
utilized injection intervals once every 2 weeks
and found it to be safe and effective as well.
Kontochristopoulus et al. demonstrated
different results than in the study conducted
by Uppal et al. likely because the keloids were
more exposed to treatment permitting better
responses. The unique method of 5-FU
tattooing reportedly had limited side effects.
Sadeghinia and Sadeghinia attributed their low
side effect profile to the extended intervals
between intralesional treatments (every
4 weeks instead of every 1–2 weeks) [35].
Likewise, the injection technique is plausible
source of adverse effects. Nanda and Reddy
encountered a much higher proportion of
patients with ulceration following treatment
and cited this for injection of 5-FU directly into
the keloid. They suggested intralesional
injections underneath the keloid; however,
Fitzpatrick refuted their speculation and
encouraged direct injection of 5-FU/TAC into
the keloid [18].
With respect to the rates of reoccurrence,
Wilson et al. demonstrated the lowest
reoccurrence of all studies at 3.75%, which
may have been the result of previous excision
plus the addition of 5-FU in addition to
botulism toxin. This was in contrast to
Kontochristopoulus et al. who reported the
highest reoccurrence of all the studied
included of 47%; this may be attributed to the
longer follow-up periods used in this study.
Many studies utilized very short follow-up
periods (\1 year), which is too short to draw
conclusions on recurrence. For this reason, the
majority of studies report a very low
reoccurrence rate, and five studies report no
reoccurrence. Additionally, the existence of an
unintended inclusion bias cannot be excluded,
as study protocols may favor patients who
produce positive results.
Strengths and Limitations
This review is one of the first to provide a
comprehensive, head-to-head comparison of
5-FU monotherapy and its combination with
adjuvant therapies including corticosteroids
and lasers for the treatment of HTSs and
keloids. The main benefit of this study is its
ability to provide the most relevant,
evidenced-based clinical data to clinicians
posed with the everyday challenge of
problematic scars and dissatisfied patients.
Direct comparison of various studies is
significantly limited by the poor level of
evidence available on 5-FU in the context of
scar therapy. Additionally, there was substantial
heterogeneity among study designs including,
but not limited to, the duration of scars,
previous treatment failures, treatment
intervals, and the number of sessions and
injections. HTSs and keloids are similar but
distinct pathological entities. Most studies
grouped these lesions together and provided
no consistent definition. Even more, outcome
evaluations were largely varied, with different
studies making use of non-standardized
subjective and objective measurements, which,
under those circumstances, complicate any
direct comparisons. Any possible outcome
bias, let alone general underlying factors such
as the scar location, skin types, sex, race, genetic
factors, immune response, and tension across
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suture lines, as well as individual fibroblast
activity, is concerning and difficult to assess.
CONCLUSION
Further studies are needed to better elucidate
the fundamental pathophysiology of HTSs and
keloids. Greater understanding of these
complex mechanisms will permit the
development of more specific treatments to
target specific pathways. As a whole, 5-FU is
an effective remedy for HTSs and keloids if
appropriately administered. Information from
the data currently published suggests that 5-FU
is a useful agent for treatment in monotherapy,
but more so in combination with other agents,
particularly low-dose corticosteroids [5].
Physicians should consider the utility of 5-FU
therapy as an alternative treatment strategy in
patients who have failed conventional
treatments and are experiencing, or would like
to avoid, the undesirable long-term adverse
effects of corticosteroid use [5].
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